 |
|
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Yi-wen Shi, Jian-Gao Fan
Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online 2022 Dec 14 DOI: https://doi.org/10.3350/cmh.2022.0401
|
|
Citations to this article as recorded by
 MAP17 is a Novel NASH Progression Biomarker Associated with Macrophage Infiltration, Immunotherapy Response, and Oxidative Stress
Zhiwei Huang, Jiatong Chen, Shenglu Liu, Xin Xiang, Yang Long, Peng Tan, Wenguang Fu
Journal of Inflammation Research.2025; Volume 18: 601. CrossRef A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis
Jeayeon Park, Goh Eun Chung, Yoosoo Chang, So Eun Kim, Won Sohn, Seungho Ryu, Yunmi Ko, Youngsu Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
Gut and Liver.2025; 19(1): 126. CrossRef Agile 3+ and Metabolic Dysfunction-Associated Fatty Liver Disease:
Detecting Advanced Fibrosis based on Reported Liver Stiffness
Measurement in FibroScan and Laboratory Findings
Mohammadjavad Sotoudeheian
The International Journal of Gastroenterology and Hepatology Diseases.2024;[Epub] CrossRef
|